DVAX Dynavax Technologies Corp
- Stocks
- Healthcare
- NASDAQ: DVAX
Price (delayed)
$11.03
Market cap
$1.29B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.42
Enterprise value
$1.48B
Relative Growth:
Rel. Growth:
50
Relative Strength:
Rel. Strength:
26
Relative Valuation:
Rel. Valuation:
15
Relative Profitability:
Rel. Profitability:
31
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of
Highlights
The company's gross profit rose by 28% YoY and by 8% QoQ
DVAX's revenue is up by 27% year-on-year and by 7% since the previous quarter
DVAX's quick ratio has shrunk by 55% YoY and by 45% QoQ
Dynavax Technologies's equity has decreased by 23% YoY and by 7% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.dynavax.com
Key stats
What are the main financial stats of DVAX
Market
Valuations
Earnings
Shares outstanding
117.27M
Market cap
$1.29B
Enterprise value
$1.48B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.68
Price to sales (P/S)
4.16
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.68
Revenue
$316.27M
Gross profit
$261.97M
Operating income
-$751,000
Net income
-$52.73M
EBIT
-$42.48M
EBITDA
-$34.28M
Free cash flow
$66.07M
Per share
Balance sheet
Liquidity
EPS
-$0.42
EPS diluted
-$0.46
Free cash flow per share
$0.55
Book value per share
$4.12
Revenue per share
$2.65
TBVPS
$7.68
Total assets
$918.45M
Total liabilities
$424.29M
Debt
$285.5M
Equity
$494.16M
Working capital
$667.48M
Debt to equity
0.58
Current ratio
6.65
Quick ratio
5.81
Net debt/EBITDA
-5.44
Margins
Efficiency
Dividend
EBITDA margin
-10.8%
Gross margin
82.8%
Net margin
-16.7%
Operating margin
-0.2%
Return on assets
-5.4%
Return on equity
-9.2%
Return on invested capital
-4%
Return on capital employed
-5.3%
Return on sales
-13.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DVAX stock price
How has the Dynavax Technologies stock price performed over time
Intraday
7.09%
1 week
6.06%
1 month
8.78%
1 year
-10.25%
YTD
-13.63%
QTD
11.08%
Financial performance
How have Dynavax Technologies's revenue and profit performed over time
Revenue
$316.27M
Gross profit
$261.97M
Operating income
-$751,000
Net income
-$52.73M
Gross margin
82.8%
Net margin
-16.7%
The company's operating margin has surged by 97% YoY and by 94% QoQ
DVAX's operating income has soared by 95% year-on-year and by 92% since the previous quarter
The company's gross profit rose by 28% YoY and by 8% QoQ
DVAX's revenue is up by 27% year-on-year and by 7% since the previous quarter
Price vs fundamentals
How does DVAX's price correlate with its fundamentals
Growth
What is Dynavax Technologies's growth rate over time
Valuation
What is Dynavax Technologies stock price valuation
P/E
N/A
P/B
2.68
P/S
4.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.68
DVAX's EPS is up by 14% from the previous quarter
DVAX's P/B is 58% below its 5-year quarterly average of 6.0 and 3.8% below its last 4 quarters average of 2.6
Dynavax Technologies's equity has decreased by 23% YoY and by 7% from the previous quarter
DVAX's revenue is up by 27% year-on-year and by 7% since the previous quarter
The P/S is 25% less than the 5-year quarterly average of 5.2 and 25% less than the last 4 quarters average of 5.2
Efficiency
How efficient is Dynavax Technologies business performance
DVAX's ROS is up by 19% from the previous quarter
Dynavax Technologies's ROA has increased by 10% from the previous quarter
Dynavax Technologies's return on invested capital has increased by 9% QoQ
The ROE has grown by 6% from the previous quarter
Dividends
What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DVAX.
Financial health
How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 116% higher than its total liabilities
DVAX's quick ratio has shrunk by 55% YoY and by 45% QoQ
Dynavax Technologies's current ratio has shrunk by 53% YoY and by 44% QoQ
Dynavax Technologies's debt is 42% less than its equity
The debt to equity has grown by 49% YoY and by 7% from the previous quarter
Dynavax Technologies's equity has decreased by 23% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.